NCT00228852View on ClinicalTrials.gov

IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency

PHASE1/PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

Not specified

Study Completion Date

November 30, 2006

Conditions

T-Cell Immune Deficiency DiseasesSevere Combined Immunodeficiency

Interventions

DRUG

Busulfan, Fludarabine and ATG

Trial Locations (1)

30322

Children's Healthcare of Atlanta, Atlanta

All Listed Sponsors

lead

Emory University

OTHER

NCT00228852 - IMM 0212: Busulfan With Fludarabine and Antithymocyte Globulin as Preparative Therapy for Hematopoietic Stem Cell Transplant for the Treatment of Severe Congenital T-Cell Immunodeficiency | Biotech Hunter | Biotech Hunter